miR-210高表达与乳腺癌预后关系的meta分析
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:

吴阶平医学基金(320.6750.12283)


Prognostic value of miR-210 in breast cancer:A meta-analysis
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:探讨miR-210高表达与乳腺癌患者预后的关系-方法:检索PubMed-EMBASE-Web of Science和CNKI等数据库中关于miR-210高表达与乳腺癌预后关系的文献资料,按纳入标准筛选出相关文献,提取总生存率 (overall survival,OS)-无复发生存率(recurrence-free survival,RFS)和无病生存率(disease-free survival,DFS)的风险比(hazard ratio,HR)及其95%可信区间(CI),用Stata软件进行分析合并-结果:按标准共纳入文献6篇,病例数585例,meta分析显示:和低表达组相比,miR-210高表达组OS的合并HR值为2.29(95%CI:0.89~5.91,P=0.086);miR-210高表达组DFS/RFS的合并HR值为2.81(95%CI:1.35~5.87,P=0.006)-结论:以现有相关研究结果的meta分析显示,miR-210的高表达是乳腺癌临床预后的不良因素-

    Abstract:

    Objective:To summarize the predicting role of increased miR-210 expression for survival in patients with breast cancer. Methods:All of relevant studies were identified by searching PubMed,EMBASE,Web of Science and CNKI. Pooled hazard ratios(HRs)with 95% confidence intervals(CIs) for overall survival(OS),recurrence-free survival(RFS),and disease-free survival(DFS)were calculated by Stata 12.0 software. Results:A total of 585 cases from 6 eligible studies were involved for this global meta-analysis. For OS,the pooled HR of higher miR-210 expression in breast cancer was 2.29(95%CI:0.89~5.91,P= 0.086). And for DFS/RFS,the pooled HR of higher miR-210 expression in breast cancer was 2.81(95%CI:1.35~5.87,P=0.006). Conclusion:This meta-analysis suggests that high expression of miR-210 may predict poor survival in patients with breast cancer.

    参考文献
    相似文献
    引证文献
引用本文

陈 慧,莫 淋,徐晓帆,顾 军. miR-210高表达与乳腺癌预后关系的meta分析[J].南京医科大学学报(自然科学版),2016,(2):239-244

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2015-07-19
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2016-02-29
  • 出版日期: